196 results about "Infertility" patented technology

The invention discloses an infertility traditional Chinese medicine auxiliary diagnosis and treatment method and system based on a knowledge graph, and belongs to the technical field of auxiliary diagnosis and treatment. Constructing a medical case database, and constructing an acupuncture therapy infertility case set; constructing a medical term set for treating the infertility by acupuncture and moxibustion; based on the acupuncture therapy infertility case set and the acupuncture therapy infertility medical term set, constructing a symptom-syndrome-prescription knowledge graph; acquiring symptoms of a patient, and acquiring a diagnosis and treatment scheme corresponding to the symptoms based on a symptom-symptom-prescription knowledge graph; acquiring feedback data of the patient, and calculating a comprehensive score of the diagnosis and treatment scheme; and presetting a comprehensive score threshold, and analyzing and dynamically updating the knowledge graph. According to the method, the knowledge graph is constructed, and the symptoms, syndrome types and acupuncture prescriptions of the infertility patients are represented in a structured form, so that the standardization and interpretability of the diagnosis and treatment scheme can be improved, the optimization of the diagnosis and treatment scheme can be realized through a dynamic updating mechanism, and a scientific and intelligent solution is provided for traditional Chinese medicine auxiliary diagnosis and treatment of infertility.

Disclosed are methods of treating infertility or increasing fertility of a female subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

The invention relates to the technical field of patient diagnosis and treatment based on artificial intelligence, in particular to an infertility analysis and diagnosis and treatment auxiliary method based on artificial intelligence, which comprises the following steps: acquiring multi-source data of a patient; semantic analysis is carried out on the multi-source data of the patient, and infertility symptom feature data of the patient is recognized in combination with a machine learning algorithm; constructing a disease risk prediction model based on a deep learning algorithm, and predicting the risk probability of the infertility disease of the patient by taking the infertility symptom characteristic data of the patient as input; and based on the risk probability of the infertility disease prediction of the patient, extracting the potential cause of infertility of the patient through an association rule mining algorithm, and generating a personalized diagnosis and treatment scheme of the patient in combination with a preset medical knowledge base. Through multi-modal time series data analysis, dynamic pathogenesis mining and medical knowledge constraint verification, infertility pathogenesis accurate identification and personalized treatment scheme generation are realized, and diagnosis and treatment accuracy and clinical decision efficiency are remarkably improved.

Described here are methods and systems for the manipulation of ovarian tissues. The methods and systems may be used in the treatment of polycystic ovary syndrome (PCOS). The systems and methods may be useful in the treatment of infertility associated with PCOS.

The invention discloses a Nur77 methylation site mutation peptide based on structural modification design and application of the Nur77 methylation site mutation peptide in promoting embryo implantation, according to the mutation peptide, arginine at the 346th site of Nur77 is mutated into lysine, and methylation modification of Nur77 is reserved while phosphorylation of Nur77 is inhibited, so that the transcriptional activity of Nur77 is enhanced. It is found that the mutant peptide can promote deciduation of endometrial interstitial cells, remarkably improve deciduation disorder of infertility mice in in-vivo experiments and improve the embryo planting rate of low-fertility mice. Therefore, the mutant peptide is expected to become a new medicine for treating the uterine-derived infertility and has important clinical application value. The invention also relates to a preparation method of the mutant peptide and application of the mutant peptide in a pharmaceutical composition and a treatment method.

Compositions including FSH and hCG for use in the treatment of infertility.

The invention discloses a construction method of a novel ovarian endometriosis mouse model. Longitudinally cutting the uterus tissue of the donor mouse into small pieces; then putting the small uterus blocks into a collagenase solution for incubation; then removing collagenase from the small uterus blocks; attaching the small uterus block to the notch of the female mouse of which the envelope on the ovary surface is cut, so that the small uterus block covers the exposed ovary surface, pushing back into the abdominal cavity as soon as possible, nailing the skin and muscles by using a suturing nail, disinfecting and putting back into the mouse cage; after 24 hours of fasting, water can be freely drunk; and conventionally feeding after 24 hours. The method does not need preoperative / postoperative estradiol management, has the advantages of simplicity in operation, time saving, good effect, high molding success rate (about 90%) and the like, and is worthy of further popularization. The constructed ovarian endometriosis mouse model can evaluate the ovarian function condition and the influence of infertility, and overcomes the defect that the existing endometriosis mouse model lacks special ovarian types.

To provide a medicine for improving the state of pregnancy.SOLUTION: The present invention provides a pharmaceutical composition for improving pregnancy conditions in a human subject with pregnancy complications, comprising tacrolimus or a pharmaceutically acceptable salt thereof as an active ingredient, where the human subject has a history of repeated implantation failure (RIF), infertility, or pregnancy-induced hypertension.SELECTED DRAWING: None

Polycystic ovary syndrome (PCOS) is characterized by elevated levels of androgens, cysts in the ovaries, and irregular periods. Women with PCOS present with additional symptoms, including hirsutism, alopecia, acne, infertility, weight gain, fatigue, depression and mood changes. The present disclosure provides new compounds, salts, compositions and uses thereof in the treatment of PCOS due to elevated adrenal androgens. Further, the present disclosure provides methods for treating PCOS due to elevated adrenal androgens.

Methods using and compositions including FSH for use in the treatment of infertility are described, wherein the dose is selected based on the patient's age to optimise cumulative efficiency and / or reduce OHSS risk.

The invention provides a goat semen cryopreservation solution. The goat semen cryopreservation solution comprises melatonin and one or more of sodium citrate, fructose, yolk, glycerol, penicillin, streptomycin and tris (hydroxymethyl) aminomethane. The cryopreservation liquid is used for preserving goat semen and can improve the pregnancy rate of long-term infertility ewes.

The invention discloses a primer probe group and a kit for joint detection of mycoplasma genitalium, ureaplasma urealyticum and chlamydia trachomatis, and belongs to the technical field of molecular biological detection. The primer probe group comprises a primer probe group A for directly detecting a mycoplasma genitalium mgpB gene, a primer probe group B for directly detecting a ureaplasma urealyticum ureB gene and a primer probe group C for directly detecting a chlamydia trachomatis ompA gene; the kit comprises a PCR (Polymerase Chain Reaction) reaction solution and the primer probe group. Nucleic acid extraction is not needed, the detection cost is greatly reduced, the experiment time is shortened, meanwhile, the specificity and accuracy are still guaranteed, meanwhile, the sensitivity is improved, and the method has wide application prospects in the fields of non-gonococcal genital tract infection main pathogen detection, infertility and prenatal and postnatal care screening and the like. And the kit has important significance on clinical diagnosis, early treatment and prevention of diseases, prevalence and the like.

The systems and methods of the invention provide several improvements directed at fertility treatment. These improvements include an expert / AI system configured to guide a caregiver, e.g., a physician, through the process of providing fertility treatment. They also include a communication system between the caregiver and a patient, which is moderated by the expert / AI system.

The invention discloses a moxa stick containing traditional Chinese medicine components for treating infertility and a preparation method of the moxa stick, relates to the technical field of traditional Chinese medicine instruments, and mainly solves the technical problem of low skin permeation efficiency of the medicine components in the moxibustion process. According to the technical scheme, the preparation method comprises the following steps: preparing traditional Chinese medicine powder consisting of angelica sinensis, prepared rehmannia root, semen cuscutae, fructus lycii, ligusticum wallichii, rhizoma cyperi, salvia miltiorrhiza and borneol according to specific parts by mass, and controlling the average particle size to be 10-50 microns; the moxa and the traditional Chinese medicine powder are mixed according to the mass ratio of (3-5): 1 to form a medicine core layer; the periphery of the medicine core layer is wrapped with a pure moxa heat conduction layer with the thickness of 2-4 mm; and finally, wrapping the periphery of the heat conduction layer with a mulberry paper barrier layer with the thickness of 0.1-0.3 mm. Through the combined action of the three-layer structure, the medicine release and heat conduction path is optimized, the medicine transdermal efficiency is remarkably improved, and the high-efficiency traditional Chinese medicine moxa stick for treating infertility is prepared.

Nutraceutical food supplement for treatment of young women in post-puberty age suffering from polycystic ovary syndrome with symptoms like irregular menstruation cycles, insulin resistant diabetes, infertility, hair loss, acne and weight gain is provided. Formulations having myo-inositol and its D-chiro isomer along with plant proteins, a carbohydrate (inulin) and other plant fibres; along with well-defined proportions of vitamins (A, B1 to 6; B12 and C); several minerals like Ca, Cr, Fe, K, Mg, Mn, Na and Zn and essential amino acids like L-Glutamine, L-Lysine, and L-Taurine are provided.

This invention discloses a porous carbon-based dual-drug-loaded nanomaterial for sustained release. The material uses a thermosensitive polymer as a matrix and cellulose nanocrystals modified with cationic surfactants as a reinforcing phase, loading both hydrophilic and hydrophobic drugs. This material can be used to prepare therapeutic drugs for gynecological diseases and infertility, as well as drug delivery devices. Furthermore, this invention provides a uterine scaffold prepared using this material, which can be fabricated using 3D printing technology. Utilizing the PNIPAm hydrogel network and its temperature-responsive properties, hydrophilic drugs can be loaded at low temperatures. The high mechanical strength of CNC machining allows for the loading of hydrophobic drugs while improving the mechanical properties of the hydrogel matrix, thus solving the problems of easy detachment and bleeding in existing technologies.

The FSH and LH fusion protein is composed of a first polypeptide, a second polypeptide, a third polypeptide and a fourth polypeptide. Wherein the first polypeptide comprises a beta subunit of FSH, a beta subunit of LH, a hinge, a CH2 structural domain and a CH3 structural domain, or the beta subunit of LH, the beta subunit of FSH, the hinge, the CH2 structural domain and the CH3 structural domain from an N terminal to a C terminal; the second polypeptide comprises a hinge, a CH2 structural domain and a CH3 structural domain from the N terminal to the C terminal; the third polypeptide and the fourth polypeptide are both composed of alpha subunits of FSH. The FSH and LH fusion protein has the functions of FSH and LH at the same time; meanwhile, compared with recombinant or natural FSH and LH, the heterodimer has a longer half-life period, can complement gonadotropin in a long-acting, mild and continuous manner, and is suitable for various FSH and LH deficiency related diseases such as male hypogonadotropin gonad hypofunction, female pituitary insufficiency, hypogonadotropin amenorrhea or hypogonadotropin infertility. The medicine economy is better, and the patient compliance is better.

Methods using and compositions including FSH for use in the treatment of infertility are described, wherein the dose is selected based on the patient's age to optimise cumulative efficiency and / or reduce OHSS risk.

The present invention relates to the technical field of infertility treatment, and particularly to the application of urofollitropin for injection combined with letrozole in the preparation of a kit for infertility. The present invention for the first time combines urofollitropin for injection and letrozole to prepare soluble microneedles. Specifically, urofollitropin for injection and letrozole are used as drug active ingredients, and the drug active ingredients are loaded in the form of PLGA-chitosan cross-linked microspheres to prepare soluble microneedles. Through verification and analysis, it is found that the soluble microneedles can effectively solve the problem of medication compliance existing in the prior art and can greatly improve the technical effect of traditional treatment methods.

LNPs can penetrate uterine mucosa to deliver therapeutic or prophylactic agents such as functional nucleic acids to the endometrium. Targeting of the LNPs using ligands expressed at particular times in an endometrial cycle ensures that the LNPs penetrate and release the mRNA primarily to the tissue associated with the peak time period for implantation, thereby providing a means to address infertility, as well as for treatment of other disorders such as cancer.

The present invention relates to a Lactobacillus salivarius strain deposited at the Spanish Type Culture Collection (CECT) under the accession number 5713, or a mutant thereof, for use in the treatment and / or prevention of infertility or recurrent miscarriage in a female subject. Furthermore, the present invention relates to an in vitro monitoring method for monitoring the therapeutic effect of the treatment of infertility or recurrent miscarriage in a female subject with a Lactobacillus salivarius strain deposited at the CECT under the accession number 5713, or a mutant thereof.

The invention discloses a formula and application of a compound infertility agent containing clarithromycin and quinestrol and based on CYP enzyme activity inhibition. The clarithromycin composition comprises clarithromycin, quinestrol and baits. The CYP enzyme inhibitor and the endocrine sterilant are combined for use, so that the synergist can effectively inhibit the activity of CYP enzyme in tissues such as livers of rats, the metabolic clearance rate of the sterilant is remarkably reduced, and the oral bioavailability and the system exposure level of the sterilant are improved. Therefore, when the same infertility effect is achieved, the use dosage of the infertility agent can be greatly reduced, so that the cost is saved, and the environmental load is reduced; or under the same dosage, a more thorough and more lasting population sterility effect can be obtained, and the practicability and competitiveness of a pest mouse sterility control technology are greatly improved.

The invention discloses a pharmaceutical composition for treating corpus luteum insufficiency type infertility as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The technical problem to be solved is to provide the pharmaceutical composition for treating the LPD type infertility, which is simpler in formula, lower in cost and better in treatment effect. According to the technical scheme, the pharmaceutical composition is prepared from the following raw materials: codonopsis pilosula, astragalus membranaceus, fried rhizoma atractylodis macrocephalae, angelica sinensis, semen cuscutae, fried eucommia ulmoides, fried teasel root, honey-fried licorice root, processed radix aconiti carmichaeli and cornu cervi degelatinatum. The pharmaceutical composition provided by the invention can improve ovarian injury, ferroptosis phenomenon, embryo implantation disorder, uterine artery blood perfusion and the like caused by LPD, and is helpful for various pathological problems related to LPD.

The present inventive concept is related to a modified follicle-stimulating hormone (FSH), in particular, a hypo-glycosylated form of FSH, as well as compositions and formulations including, nucleic acids encoding, cell lines expressing, and methods of using the hypo-glycosylated FSH as disclosed herein. These methods of use include methods of treating infertility, methods of inducing follicle growth and / or maturation, methods of inducing oocyte / egg growth and / or maturation, methods of stimulating sex steroid secretion, methods of treating or preventing bone density loss, and methods of treating or preventing fatty tissue accumulation.

The invention relates to the technical field of probiotic application, in particular to application of lactobacillus crispatus HC1261 in preparation of a microbial agent for improving female reproductive health and a composition for improving vagina inflammation. The lactobacillus crispatus HC1261 is preserved in the China General Microbiological Culture Collection Center (CGMCC) on May 16, 2023, the preservation address is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC No.27355; the microbial inoculum for improving female reproductive health can reduce the load of the ureaplasma urealyticum in the vagina. The lactobacillus crispatus HC1261 can be used for pertinently reducing the load of the ureaplasma urealyticum in the vagina, and can be used for reducing the related health risks of urethritis, cervicitis, pelvic inflammation, infertility and the like caused by the ureaplasma urealyticum.

Methods using and compositions including FSH for use in the treatment of infertility are described, wherein the dose is selected based on the patient's age to optimise cumulative efficiency and / or reduce OHSS risk.

Provided herein are methods and compositions comprising pulsatile follicle stimulating hormone (FSH). The pulsatile FSH may be used in methods of treating infertility, restoring normal hormonal levels, stimulating secretion of a sex steroid, treating or preventing fatty tissue accumulation, treating or preventing loss of bone density, preventing ovarian inflammation, and / or promoting metabolic health.

Disclosed herein are methods and systems for predicting sperm quality by determining methylation in different gene promoters. Also disclosed herein, are methods and systems for determining methylation variability of an individual promoter. Additionally, methods of treatment for infertility or diminished fertility are described herein. Also described herein are kits, such as kits comprising arrays.

Materials and methods of treating a patient with type 2 diabetes mellitus, metabolic syndrome, obesity, infertility, high blood pressure, hyperthyroidism, and hypothyroidism, hyperlipidaemia, osteoporosis, osteoarthritis, hypoadrenalism, polycystic ovary syndrome, or Parkinson's disease comprising administering a therapeutically effective amount of ex vivo cultured activated peripheral blood mononuclear cells (PBMCs) to the patient. The ex vivo cultured activated cells are activated and cultured in a presence of a cytokine and may be autologous or allogeneic relative to the patient.

Tracking ovulatory hormone levels is key to detecting fertility windows and providing actionable information for facilitating or preventing conception, as well as assessing and managing infertility and other conditions associated with hormone imbalances. Conventional fertility methods suffer drawbacks associated with invasive sampling, inadequate prediction accuracies, or repetitive user intervention. To overcome these and other limitations, the present Applicants developed a wearable device for contemporaneous monitoring of estradiol, progesterone, and luteinizing hormone and physiological biomarkers (temperature, pH). Flexible field-effect transistors functionalized with biomarker-specific aptamers enabled sensitive and selective determination of the three principal ovulatory hormones across physiological ranges in artificial human sweat. By including an on-demand iontophoretic sweat sampling feature, the present Applicants established an integrated wearable platform for high-accuracy, minimally invasive, rapid, and personalized ovulatory status monitoring.